⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

Lewy body dementia is the second most common degenerative dementia. Approximately 1.4 million Americans live with LBD. It is caused by abnormal alpha-synuclein protein deposits (Lewy bodies) in the brain. It is frequently misdiagnosed as Alzheimer’s disease or Parkinson’s disease.
LBD is not just memory loss. It causes a distinctive combination of cognitive fluctuations, visual hallucinations, parkinsonism (stiffness, slowness, tremor), REM sleep behavior disorder, and autonomic dysfunction. The mix of symptoms is what distinguishes it from Alzheimer’s.
AVOID MOST ANTIPSYCHOTICS — this can save a life. People with LBD have severe neuroleptic sensitivity. Drugs like haloperidol, risperidone, and olanzapine can cause catastrophic reactions. If an antipsychotic is absolutely needed, only pimavanserin (Nuplazid) or very low-dose quetiapine should be considered under specialist care.
Cholinesterase inhibitors are the most evidence-based treatment. Rivastigmine (Exelon) has the strongest evidence for LBD cognitive and psychiatric symptoms. Donepezil is also used. These medications can improve cognition, reduce hallucinations, and help with behavioral symptoms.
There is no disease-modifying therapy yet. Current treatments manage symptoms but do not stop the underlying disease. Anti-alpha-synuclein antibodies (prasinezumab) are in clinical trials but have not yet proven efficacy in LBD specifically.
REM sleep behavior disorder (RBD) often appears years before other symptoms. Acting out dreams — punching, kicking, yelling during sleep — is a strong early warning sign of LBD. If you or your partner has RBD, seek evaluation by a movement disorder neurologist.
Get to a specialist. LBD requires a neurologist experienced in Lewy body disorders — ideally a movement disorder specialist or behavioral neurologist. Misdiagnosis leads to harmful medications and missed treatment opportunities.
Caregiver support is essential. LBD caregiving is exceptionally demanding because of the combination of cognitive, motor, psychiatric, and sleep symptoms. Caregiver burnout rates are among the highest of any dementia. Use the resources in this guide.

▼ Collapse

Understanding Lewy Body Dementia

Lewy body dementia (LBD) is a progressive brain disease caused by abnormal deposits of a protein called alpha-synuclein inside nerve cells. These deposits, called Lewy bodies, damage and eventually destroy neurons in areas of the brain critical for thinking, movement, behavior, and mood.

LBD is an umbrella term that includes two related conditions:

Dementia with Lewy bodies (DLB): Cognitive symptoms (thinking and memory problems) appear first or within one year of movement symptoms.
Parkinson’s disease dementia (PDD): A person with established Parkinson’s disease (diagnosed for at least one year with motor symptoms) later develops dementia.

Both DLB and PDD involve the same underlying pathology — Lewy bodies — and many of the same symptoms. The main difference is the timing: which comes first, the cognitive or the motor symptoms. Treatment approaches overlap significantly.

Approximately 1.4 million people in the United States are estimated to have LBD
LBD accounts for 5–10% of all dementia cases (some estimates reach 15–25% when including PDD), making it the second most common degenerative dementia after Alzheimer’s
Average age at onset is typically 50 to 80 years, with most diagnosed after 65
LBD is slightly more common in men than women
An estimated 50% or more of LBD cases are misdiagnosed, most commonly as Alzheimer’s disease, Parkinson’s disease, or a psychiatric disorder
Average survival from symptom onset is approximately 5 to 8 years, though this varies widely

The exact cause of LBD is not fully understood. The disease is driven by the misfolding and accumulation of alpha-synuclein protein in neurons. What triggers this misfolding is unknown in most cases.

Genetics: Most LBD cases are not directly inherited. However, having a first-degree relative with LBD or Parkinson’s disease modestly increases risk. Variants in the GBA (glucocerebrosidase), APOE, and SNCA genes have been linked to increased susceptibility.
Age: The strongest risk factor. LBD is rare before age 50.
Sex: Men are affected slightly more often than women.
Parkinson’s disease: Approximately 50–80% of people with Parkinson’s disease will eventually develop cognitive impairment or dementia.

The most important concept in this guide: LBD is not Alzheimer’s disease. It requires different medications, different management strategies, and carries specific dangers (especially from antipsychotics) that do not apply to Alzheimer’s. Getting the correct diagnosis is the single most important step, because it changes everything about how the disease is managed.

Key Developments in LBD

While there is no cure for LBD, the understanding and management of the disease has improved significantly in recent years. Here are the most important developments:

AVAILABLE The alpha-synuclein seed amplification assay (SAA) can detect misfolded alpha-synuclein in cerebrospinal fluid (CSF) with very high accuracy (sensitivity >90%, specificity >95% for synucleinopathies). This test, which requires a lumbar puncture, can confirm that a person has a Lewy body disorder — distinguishing LBD from Alzheimer’s disease with unprecedented reliability. The SAA has moved from research to clinical availability at select academic centers and is transforming early and accurate diagnosis of LBD.

FDA-APPROVED Pimavanserin is a selective serotonin inverse agonist (5-HT2A) that was FDA-approved in 2016 for hallucinations and delusions associated with Parkinson’s disease psychosis. Unlike traditional antipsychotics, it does not block dopamine receptors and therefore does not worsen parkinsonism. It is increasingly used off-label for DLB psychosis. The HARMONY trial demonstrated that pimavanserin reduced psychosis relapse in neurodegenerative conditions broadly. It represents the safest available antipsychotic option for people with LBD.

FDA-APPROVED Rivastigmine (Exelon) is the cholinesterase inhibitor with the most evidence in LBD. It is FDA-approved for mild-to-moderate Parkinson’s disease dementia (PDD) and widely used off-label for DLB. Clinical trials have shown it improves cognitive function, reduces apathy and hallucinations, and may slow functional decline. The transdermal patch formulation improves tolerability compared to oral dosing. LBD patients often respond more robustly to cholinesterase inhibitors than Alzheimer’s patients because cholinergic deficits are more profound in LBD.

GUIDELINE The 2017 Fourth Consensus Report updated the diagnostic criteria for DLB, adding REM sleep behavior disorder as a core clinical feature (previously it was suggestive only) and incorporating new biomarkers including DaT-SPECT imaging and polysomnography-confirmed RBD. These updated criteria have improved diagnostic accuracy and earlier identification of DLB.

INVESTIGATIONAL Prasinezumab is a monoclonal antibody targeting aggregated alpha-synuclein, currently in phase 2 trials for Parkinson’s disease (PASADENA, PADOVA). While initial results in PD showed some signal on motor progression, the primary endpoints were not met. Trials specifically in DLB are being planned. Cinpanemab, another anti-alpha-synuclein antibody, failed its phase 2 trial (SPARK) and development was discontinued. The field continues to pursue alpha-synuclein as a therapeutic target despite these setbacks.

GUIDELINE DLB management is guided by the Fourth Consensus Report of the DLB Consortium (McKeith et al., Neurology 2017) for diagnosis, the UK NICE dementia guideline (NG97), the Movement Disorder Society PDD criteria, and Lewy Body Dementia Association (LBDA) resources. Across these, the consistent recommendations are: cholinesterase inhibitors (rivastigmine, donepezil) for cognitive and behavioral symptoms; strong caution against antipsychotics (severe neuroleptic sensitivity); and melatonin and/or clonazepam for REM sleep behavior disorder. DLB is recognized as requiring management distinct from Alzheimer’s disease. (Note: there is no standalone American Academy of Neurology practice guideline specific to DLB; AAN content appears in Continuum review articles.)

Getting Diagnosed — Why It Matters So Much

An accurate diagnosis of LBD is critically important because it directly determines which medications are safe, which are dangerous, and what symptoms to expect. Misdiagnosis as Alzheimer’s disease can lead to the prescription of antipsychotics that can be devastating in LBD. Misdiagnosis as pure Parkinson’s disease can mean cognitive and psychiatric symptoms are overlooked.

Diagnosis of LBD is primarily clinical — based on a thorough history, neurological examination, and cognitive testing. Key elements include:

Detailed history from patient AND care partner: The care partner’s observations are often more revealing than the patient’s self-report, especially regarding fluctuations, visual hallucinations, and sleep behavior.
Cognitive testing: LBD typically affects attention, executive function, and visuospatial abilities more than memory in early stages — unlike Alzheimer’s where memory loss predominates.
Motor examination: Parkinsonism (bradykinesia, rigidity, rest tremor, postural instability) may be present at diagnosis or develop later.
Sleep history: Specific questioning about REM sleep behavior disorder — dream enactment, talking, shouting, punching, kicking during sleep.
Psychiatric assessment: Visual hallucinations, fluctuating cognition, depression, apathy, anxiety, delusions.

DaT-SPECT scan (DaTscan): An imaging test that measures dopamine transporter levels in the brain. Reduced uptake in the striatum supports a diagnosis of DLB over Alzheimer’s. This is one of the most useful tests for distinguishing DLB from AD.
Polysomnography (sleep study): Confirms REM sleep behavior disorder by showing REM sleep without the normal muscle paralysis (REM sleep without atonia). Polysomnography-confirmed RBD is a core diagnostic feature of DLB.
Alpha-synuclein seed amplification assay (SAA): A CSF test that can detect misfolded alpha-synuclein. High sensitivity and specificity for synucleinopathies. Increasingly available at academic centers.
MIBG cardiac scintigraphy: Measures sympathetic nerve innervation of the heart. Reduced uptake supports a Lewy body diagnosis. More commonly used in Japan; available at some US academic centers.
Brain MRI: Used primarily to exclude other conditions. In LBD, the hippocampus is often relatively preserved compared to Alzheimer’s disease.
EEG: May show posterior slow-wave activity with periodic fluctuations in DLB.
FDG-PET: Shows hypometabolism in occipital lobes in DLB (the “cingulate island sign”), which helps distinguish it from Alzheimer’s.

Referral routing. If LBD is suspected, the patient should be referred to a movement disorder neurologist or behavioral neurologist with experience in Lewy body disorders. General neurologists and psychiatrists may not be familiar with the specific medication sensitivities and management strategies unique to LBD. A cognitive neurology or dementia specialty clinic is ideal.

Could my symptoms be caused by Lewy body dementia rather than Alzheimer’s or Parkinson’s alone?
Have you considered ordering a DaTscan to help distinguish DLB from Alzheimer’s?
Is the alpha-synuclein seed amplification assay (SAA) test available at your center?
Should I have a sleep study to evaluate for REM sleep behavior disorder?
Are any of my current medications potentially dangerous if I have LBD (especially antipsychotics, anticholinergics, or certain anti-nausea drugs)?
Can you refer me to a movement disorder specialist or behavioral neurologist experienced with Lewy body dementia?
Should I have genetic testing (GBA gene)?
What is the difference between DLB and Parkinson’s disease dementia, and does it matter for my treatment?

Core and Suggestive Features of DLB

The Fourth Consensus Criteria (McKeith 2017) define four core clinical features and several suggestive and supportive features. Probable DLB requires dementia plus two or more core features, or one core feature plus one or more indicative biomarkers.

Feature	Description	How Common
Core Clinical Features
Fluctuating cognition	Pronounced variations in attention and alertness, sometimes within the same day. Periods of clarity alternating with confusion, staring, or drowsiness.	~60–80%
Recurrent visual hallucinations	Detailed, well-formed visual hallucinations — typically of people, animals, or objects. Often recognized by the patient as not real (at least initially). May be nonthreatening or distressing.	~60–80%
REM sleep behavior disorder	Acting out vivid dreams during REM sleep — talking, shouting, punching, kicking. May precede cognitive symptoms by years or decades.	~50–80%
Parkinsonism	One or more of: bradykinesia (slowness), rest tremor, rigidity (stiffness). Often symmetric or mild compared to typical Parkinson’s disease.	~70–90%
Suggestive Features
Severe neuroleptic sensitivity	Severe adverse reactions to antipsychotic medications, including worsening parkinsonism, sedation, neuroleptic malignant syndrome, or death.	~30–50% of those exposed
Postural instability and repeated falls	Falls are common and often occur early in the disease.	~30–50%
Autonomic dysfunction	Orthostatic hypotension, constipation, urinary problems, erectile dysfunction, excessive sweating.	~50–70%
Hypersomnia	Excessive daytime sleepiness, often profound.	~40–60%
Hyposmia	Reduced sense of smell, often preceding other symptoms.	~50–70%

DLB vs. Parkinson’s Disease Dementia — Does It Matter?

DLB and PDD are caused by the same underlying pathology (Lewy bodies) and share many symptoms. The clinical distinction is based on the “one-year rule”:

DLB: Cognitive symptoms appear before or within one year of parkinsonism.
PDD: Parkinson’s disease motor symptoms have been present for at least one year before dementia develops.

For treatment purposes, DLB and PDD are managed very similarly. Cholinesterase inhibitors help both. The same antipsychotic cautions apply to both. The same motor symptom treatments are used. Where differences exist, they are noted in the treatment sections below.

Practical takeaway: Whether you are diagnosed with DLB or PDD, the core management principles — cholinesterase inhibitors for cognition, extreme caution with antipsychotics, careful dopaminergic therapy for motor symptoms, melatonin for RBD — are the same. Do not get stuck on the label. Focus on symptoms and safe treatment.

Is my diagnosis DLB or PDD, and does the distinction change my treatment?
What core and suggestive features do I have?
Have all my current medications been reviewed for safety in LBD?
Should I carry a medical alert card about neuroleptic sensitivity?
Is genetic counseling recommended for my family members?
What should I expect in terms of disease progression?
Should I complete advance directives and power of attorney documents now while I am able?

Treating Cognitive Symptoms

Cognitive symptoms in LBD include problems with attention, executive function (planning, organizing, problem-solving), visuospatial abilities, and eventually memory. Fluctuating cognition — good days and bad days, or even good and bad hours — is a hallmark of the disease.

RECOMMENDED Cholinesterase inhibitors are the most important medications for LBD cognitive and behavioral symptoms. They work by increasing acetylcholine, a brain chemical that is severely depleted in LBD (even more so than in Alzheimer’s).

Rivastigmine (Exelon): The cholinesterase inhibitor with the strongest evidence in LBD. FDA-approved for Parkinson’s disease dementia. Available as a transdermal patch (preferred for tolerability) or oral capsule. Typical dose: patch 4.6 mg/24h, increased to 9.5 mg/24h or 13.3 mg/24h. Benefits include improved cognition, reduced apathy, fewer hallucinations, and improved behavioral symptoms.
Donepezil (Aricept): FDA-approved for Alzheimer’s disease, widely used off-label for DLB. Evidence from clinical trials shows benefit in DLB cognition and global function. Typical dose: 5–10 mg daily. Generally well tolerated.
Galantamine (Razadyne): Less studied in LBD but may be used. Also a cholinesterase inhibitor with additional nicotinic receptor modulation.

Important: LBD patients often show a more robust response to cholinesterase inhibitors than Alzheimer’s patients. If a cholinesterase inhibitor is stopped abruptly, there may be a rapid and sometimes irreversible cognitive decline. Any dose changes should be gradual and supervised.

Memantine, an NMDA receptor antagonist, is sometimes added to a cholinesterase inhibitor for moderate-to-advanced LBD. Evidence in DLB is limited and mixed. Some studies suggest mild cognitive benefit; others show no effect or possible worsening of hallucinations. In PDD, evidence is slightly more favorable. If used, it should be added carefully with close monitoring for any worsening of symptoms.

Should I start a cholinesterase inhibitor, and which one do you recommend?
Would the rivastigmine patch be better tolerated than the oral form?
Is memantine appropriate for my stage of disease?
If I stop the cholinesterase inhibitor, could my cognition decline rapidly?
What cognitive changes should we monitor for to know if the medication is working?
Are there non-medication approaches that can help with cognition (exercise, cognitive engagement, music therapy)?
Should we consider a clinical trial?

Managing Motor Symptoms (Parkinsonism)

Many people with LBD develop motor symptoms similar to Parkinson’s disease: slowness (bradykinesia), stiffness (rigidity), tremor, shuffling gait, and postural instability. Motor symptoms in DLB tend to be less responsive to levodopa than in typical Parkinson’s disease, and the risk of exacerbating psychiatric symptoms is higher.

FIRST-LINE FOR MOTOR SYMPTOMS Carbidopa/levodopa is the preferred medication for motor symptoms in LBD. However, it must be used cautiously:

Start at the lowest effective dose and increase slowly (“start low, go slow”)
Motor response may be partial — less dramatic than in typical Parkinson’s disease
Higher doses can worsen hallucinations, confusion, and behavioral symptoms
The goal is to find the balance between improved mobility and psychiatric side effects
If hallucinations worsen with levodopa, adding or optimizing a cholinesterase inhibitor may help manage both

Dopamine agonists (pramipexole, ropinirole, rotigotine): These are commonly used in Parkinson’s disease but carry a much higher risk of causing or worsening hallucinations, delusions, and impulse control disorders in LBD patients. Generally avoided in DLB; used with extreme caution in PDD.
Anticholinergics (trihexyphenidyl, benztropine): These worsen cognition and can cause confusion, hallucinations, and delirium. Absolutely contraindicated in LBD.
Amantadine: Can worsen hallucinations and confusion. Generally avoided in LBD.

Physical therapy is essential for maintaining mobility, balance, and reducing fall risk in LBD. Evidence-based approaches include:

Balance and gait training: Targeted exercises to reduce falls
Strength training: Maintaining muscle mass for mobility and independence
Aerobic exercise: Walking, cycling, or swimming — may have neuroprotective effects
Occupational therapy: Adapting the home environment for safety
Speech/language therapy: For voice and swallowing difficulties

Managing Psychiatric Symptoms

Psychiatric symptoms are among the most challenging aspects of LBD for patients and caregivers. They include visual hallucinations, delusions, agitation, anxiety, depression, and apathy.

Visual hallucinations are a hallmark of LBD, occurring in 60–80% of patients. They are typically well-formed images of people, children, animals, or objects. Management approaches:

Non-pharmacologic first: Improve lighting, reduce visual clutter, correct vision, redirect attention, reassure calmly. Not every hallucination needs medication — if hallucinations are not distressing, they may not require treatment.
Cholinesterase inhibitors: Often reduce hallucination frequency and severity. This is the first pharmacologic approach.
Pimavanserin (Nuplazid): The safest antipsychotic option for LBD psychosis. Does not block dopamine, so does not worsen motor symptoms. FDA-approved for PD psychosis. Typical dose: 34 mg daily. May take 4–6 weeks for full effect.
Quetiapine (very low dose): If pimavanserin is unavailable or ineffective, quetiapine at very low doses (12.5–50 mg at bedtime) is sometimes used. It has the least dopamine-blocking activity of the conventional antipsychotics. Even so, close monitoring is required.

Common delusions in LBD include paranoia, Capgras syndrome (believing a family member has been replaced by an impostor), and misidentification. Management:

Identify triggers: Pain, constipation, urinary tract infection, medication changes, sleep deprivation, and environmental overstimulation can all trigger or worsen behavioral symptoms.
Cholinesterase inhibitors: May reduce delusions and agitation.
Redirect and reassure: Arguing with someone experiencing delusions is counterproductive. Redirect attention and provide calm reassurance.
Avoid antipsychotics whenever possible. If absolutely necessary, use pimavanserin or very low-dose quetiapine only.

Depression affects 30–50% of LBD patients and is an important contributor to quality of life. Treatment options:

SSRIs (sertraline, citalopram, escitalopram): Generally first-line for depression in LBD. Well tolerated in most patients.
SNRIs (venlafaxine, duloxetine): Alternative when SSRIs are insufficient. Venlafaxine may help with both depression and pain.
Avoid tricyclic antidepressants: Their anticholinergic properties can worsen cognition and cause confusion in LBD patients.
Non-pharmacologic approaches: Exercise, music therapy, social engagement, bright light therapy, and caregiver support groups.

Are my hallucinations severe enough to require medication, or can we manage them without drugs?
Is pimavanserin available and appropriate for my situation?
If quetiapine is being considered, what is the lowest dose we can start with?
Could any of my current medications be causing or worsening hallucinations?
Am I being screened for depression, and what treatment is recommended?
What should I do if I have a severe behavioral crisis at home or at night?

Managing Sleep Disorders

Sleep disturbances are nearly universal in LBD and cause significant burden for both patients and caregivers.

RBD is a core feature of LBD. People with RBD act out their dreams — punching, kicking, shouting, falling out of bed. This can injure the patient or the bed partner. RBD may precede other LBD symptoms by 10–15 years or more.

Safety measures first: Remove sharp objects from the bedside, pad the floor, consider bed rails or a low mattress on the floor, sleep in separate beds if necessary for safety.
Melatonin: The first-line pharmacologic treatment. Doses of 3–12 mg at bedtime can reduce RBD episodes with minimal side effects. Start low (3 mg) and increase gradually.
Clonazepam: Low-dose (0.25–1 mg at bedtime) is effective but must be used with caution in LBD due to risk of increased confusion, sedation, and falls. Reserved for cases not responding to melatonin.

Profound daytime drowsiness is common in LBD and can be disabling. Strategies:

Maintain a consistent sleep-wake schedule
Encourage daytime activity, bright light exposure, and short walks
Review medications for sedating effects (reduce or eliminate where possible)
Modafinil or methylphenidate may be considered in severe cases, though evidence is limited

Sleep hygiene (regular bedtime, dark room, limited napping)
Melatonin (may help with both RBD and general sleep)
Avoid: Benzodiazepines (other than low-dose clonazepam for RBD), sedating antihistamines (diphenhydramine, doxylamine — these have anticholinergic properties and can worsen confusion), and zolpidem (can cause paradoxical agitation in LBD)

Managing Autonomic Dysfunction

The autonomic nervous system — which controls blood pressure, digestion, bladder function, and temperature regulation — is commonly affected in LBD.

A significant drop in blood pressure upon standing causes dizziness, lightheadedness, and falls. Management:

Rise slowly from sitting or lying positions
Increase fluid and salt intake (if no heart failure)
Wear compression stockings or an abdominal binder
Review and reduce blood pressure medications that may be unnecessary
Fludrocortisone or midodrine may be prescribed if non-pharmacologic measures are insufficient
Droxidopa (Northera) is FDA-approved for neurogenic orthostatic hypotension

Constipation: Extremely common in LBD. Increase dietary fiber, fluids, and physical activity. Use osmotic laxatives (polyethylene glycol, MiraLAX) as needed. Avoid stimulant laxatives long-term.
Urinary urgency/frequency: May respond to bladder training and timed voiding. If medication is needed, mirabegron (Myrbetriq) is preferred over oxybutynin, which has anticholinergic effects that can worsen cognition.

Should my blood pressure be checked both lying down and standing up?
Are any of my current medications contributing to dizziness, constipation, or urinary problems?
Is melatonin appropriate for my sleep problems?
What safety measures should we put in place at night to prevent injury from RBD?
Should we consider a medication for orthostatic hypotension?

Medications to Avoid in LBD

THIS SECTION CAN SAVE A LIFE. People with Lewy body dementia are uniquely vulnerable to certain medications that are commonly prescribed in general medical settings. Sharing this information with every member of the care team, emergency departments, and hospitals is critically important.

Medication Class	Examples	Risk in LBD
First-generation antipsychotics	Haloperidol (Haldol), chlorpromazine, fluphenazine	LIFE-THREATENING. Can cause severe parkinsonism, neuroleptic malignant syndrome, coma, and death. NEVER use in LBD.
Most second-generation antipsychotics	Risperidone, olanzapine, aripiprazole, ziprasidone	HIGH RISK. Can cause severe worsening of motor symptoms, excessive sedation, and neuroleptic sensitivity reactions. Avoid.
Anticholinergic medications	Oxybutynin, diphenhydramine (Benadryl), hydroxyzine, tricyclic antidepressants, benztropine	Worsen cognition, cause confusion, hallucinations, delirium. Avoid.
Anti-nausea drugs that block dopamine	Metoclopramide (Reglan), prochlorperazine (Compazine), promethazine (Phenergan)	Worsen parkinsonism, cause severe rigidity. Use ondansetron or domperidone instead.
Dopamine agonists (in DLB)	Pramipexole, ropinirole, rotigotine	High risk of hallucinations, confusion, impulse control disorders. Generally avoid in DLB; use with extreme caution in PDD.

Practical step: Create a wallet card or medical bracelet that states: “I have Lewy body dementia. Do NOT administer haloperidol, risperidone, olanzapine, or other antipsychotic medications without contacting my neurologist. Severe neuroleptic sensitivity.” The Lewy Body Dementia Association (LBDA) offers free medical alert wallet cards at lbda.org.

class="content-section" data-stage="advanced">

Clinical Trials — Finding and Enrolling

Clinical trials are particularly important in LBD because there is no disease-modifying therapy yet approved. Trials offer access to investigational treatments and help advance the understanding of this disease.

Trial	Agent(s)	Population	NCT Number
PASADENA	Prasinezumab (anti-alpha-synuclein)	Early Parkinson’s disease	NCT03100149
PADOVA	Prasinezumab (anti-alpha-synuclein)	Early Parkinson’s disease (phase 2b)	NCT04777331
AscenD-LB / RewinD-LB	Neflamapimod (p38 MAPK inhibitor)	Dementia with Lewy bodies	NCT04001517 / NCT05869669
HARMONY	Pimavanserin	Dementia-related psychosis	NCT03325556
Various GLP-1 agonist trials	Lixisenatide (LixiPark, positive); exenatide (negative)	Parkinson’s disease (neuroprotection)	Search ClinicalTrials.gov for “GLP-1 Parkinson”

ClinicalTrials.gov (clinicaltrials.gov): Search for “Lewy body dementia” or “dementia with Lewy bodies” and filter by status (recruiting) and location.
Lewy Body Dementia Association (LBDA) Research Center: lbda.org/research — Maintains an up-to-date list of LBD clinical trials.
Fox Trial Finder (Michael J. Fox Foundation): foxtrialfinder.michaeljfox.org — Matches Parkinson’s/LBD patients to clinical trials.
Alzheimer’s Disease Research Centers (ADRC): NIH-funded centers at academic institutions often recruit for LBD studies.
Your movement disorder specialist: Ask about trials at your center or nearby academic centers.

Am I eligible for any clinical trials for LBD?
Are there disease-modifying trials (anti-alpha-synuclein, GBA-targeted) that I could participate in?
What are the risks and benefits of this trial compared to my current treatment?
Would participating in a trial require me to stop any of my current medications?
Is there a way to participate in research (biomarker studies, brain donation programs) even if I am not eligible for a drug trial?

International Access & Regulatory Landscape

LBD drug availability and diagnostic tools vary significantly by country. Here is an overview of key international differences:

Region	Key Differences
United States (FDA)	Rivastigmine FDA-approved for PDD. Pimavanserin FDA-approved for PD psychosis. DaTscan available. Alpha-synuclein SAA becoming clinically available. Donepezil used off-label for DLB.
European Union (EMA)	Rivastigmine approved for PDD. Donepezil used off-label for DLB. DaTscan widely available. Pimavanserin not yet EMA-approved. NICE (UK) recognizes DLB as distinct from Alzheimer’s and recommends cholinesterase inhibitors.
United Kingdom (NICE)	NICE recommends donepezil or rivastigmine for DLB. Galantamine as alternative. DaTscan reimbursed through NHS. Pimavanserin not available. NICE explicitly cautions against antipsychotics in DLB.
Japan (PMDA)	Donepezil specifically approved for DLB (2014) — the only country with a DLB-specific cholinesterase inhibitor approval. MIBG cardiac scintigraphy widely used and reimbursed for DLB diagnosis. Higher prevalence of PDD relative to DLB in clinical practice.
Canada (Health Canada)	Rivastigmine approved for PDD. Donepezil used off-label for DLB. DaTscan available at some centers. Alpha-synuclein SAA available at select research centers.
Global	LBD is estimated to be underdiagnosed by 50% or more worldwide. Many countries lack access to DaTscan, MIBG, or alpha-synuclein SAA. Clinical diagnosis remains the primary approach in most settings. The Fourth Consensus Criteria (McKeith 2017) are used internationally.

Lewy Body Dementia Association (LBDA, US): lbda.org
Lewy Body Society (UK): lewybody.org
DLB Consortium: International research consortium that developed the consensus diagnostic criteria
Movement Disorder Society (MDS): International society for Parkinson’s and related disorders including PDD
Parkinson’s Foundation: Resources applicable to PDD (parkinson.org)
Alzheimer’s Disease International (ADI): Global federation of Alzheimer’s and dementia associations

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is important. Understanding past failures helps you evaluate new options and avoid treatments that have already been studied and found to be ineffective or harmful.

FAILED Cinpanemab was a monoclonal antibody targeting alpha-synuclein developed by Biogen. The SPARK trial (NCT03318523) in early Parkinson’s disease failed to show any benefit on motor or non-motor outcomes. Development was discontinued in 2021. This was a significant setback for the alpha-synuclein antibody approach, though other antibodies (prasinezumab) continue in development.

FAILED Intepirdine was a serotonin 5-HT6 receptor antagonist tested for DLB in the HEADWAY-DLB trial. The phase 2 study did not meet its primary endpoint of cognitive improvement in DLB patients. While it showed some signal on gait and motor function secondary endpoints, the cognitive benefit was not significant. Development for DLB was discontinued.

HARMFUL — DE-ADOPTED Traditional antipsychotics (haloperidol, chlorpromazine) and potent atypical antipsychotics (risperidone, olanzapine) were once used for psychosis in all dementia types. In LBD, these drugs cause devastating neuroleptic sensitivity reactions in 30–50% of patients exposed, including irreversible parkinsonism, neuroleptic malignant syndrome, and death. They are now explicitly contraindicated in all major LBD guidelines.

DE-ADOPTED Anticholinergic drugs like trihexyphenidyl and benztropine, once used for tremor in Parkinson’s disease, are now recognized as dangerous in LBD. They block the same acetylcholine that cholinesterase inhibitors are trying to increase, directly worsening cognition and often precipitating delirium. They are contraindicated in all forms of LBD.

UNCERTAIN Memantine as monotherapy for DLB has produced mixed results. Some studies showed modest clinical global improvement, while others showed no benefit or possible worsening of hallucinations. It is not recommended as first-line therapy and should only be considered as an add-on to cholinesterase inhibitors in moderate-to-advanced disease.

Why this matters: If someone suggests one of these therapies, you now know its history. Always ask your neurologist: “Has this been tested in people with Lewy body dementia specifically, and what were the results?”

Are there any disease-modifying therapies in clinical trials that I might be eligible for?
Should I consider enrolling in a brain donation program for research?
Is genetic testing (especially GBA) recommended for me or my family?
What therapies have been tried and failed for LBD that I should be aware of?
How do you stay up to date on the latest LBD research and treatments?
What palliative care and hospice options should we plan for as the disease progresses?

class="content-section" data-stage="resources">

Specialty Centers

LBD outcomes and quality of life are significantly better when managed by clinicians experienced in Lewy body disorders. A second opinion from a movement disorder or cognitive neurology center is strongly recommended.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

University of Utah Center for Alzheimer’s Care, Imaging & Research

NIH-funded Alzheimer’s Disease Research Center with Lewy body dementia expertise

Location: 650 Komas Dr, Salt Lake City, UT 84108
Phone: 801-585-0303
Programs: Cognitive neurology clinic, dementia evaluation including DLB, longitudinal research studies, brain imaging, biomarker studies, and brain donation program. Part of the NIH ADRC network. Access to clinical trials for LBD and related dementias.

University of Utah Movement Disorders Program

Location: Clinical Neurosciences Center, 175 N Medical Dr E, Salt Lake City, UT 84132
Phone: 801-581-2121
Programs: Movement disorder neurology, Parkinson’s disease and PDD evaluation and management, DaTscan interpretation, deep brain stimulation, multidisciplinary care.

Intermountain Health Neurosciences

Location: Multiple locations across Utah and the Intermountain West
Phone: 801-442-2000
Programs: Neurology, neuropsychology, memory clinics, movement disorders. Community-based neuroscience care with referral pathways to academic centers.

Mayo Clinic Arizona

Location: 5777 E Mayo Blvd, Phoenix, AZ 85054
Phone: 480-301-8000
Programs: Dementia and movement disorder programs with LBD expertise. DaTscan and advanced neuroimaging.

University of Colorado — Behavioral Neurology and Dementia Program

Location: Anschutz Medical Campus, 1635 Aurora Ct, Aurora, CO 80045
Phone: 720-848-2080
Programs: Dementia evaluation, movement disorders, clinical trials. Part of the NIH ADRC network.

How to choose. University of Utah CACIR = NIH ADRC with specific DLB research and brain donation program. U of U Movement Disorders = best for motor-predominant presentations and PDD. Intermountain Health = broad neuroscience network with community access.

Information verified May 2026. Availability changes — confirm with each institution directly.

Mayo Clinic Rochester — LBD Program

Location: Rochester, MN · Phone: 507-538-3270
One of the leading LBD research centers in the world. Extensive LBD-specific clinical trials. Alpha-synuclein SAA testing available. DaTscan and MIBG imaging. Brain donation program. Dennis Dickson neuropathology laboratory.

NIH National Institute on Aging — Clinical Center

Location: Bethesda, MD · Phone: 800-411-1222
Federal research facility with LBD and synucleinopathy research programs. Clinical trials may include free treatment and travel support.

Cleveland Clinic Lou Ruvo Center for Brain Health

Location: Las Vegas, NV and Cleveland, OH · Phone: 702-483-6000 (Las Vegas) / 216-636-5860 (Cleveland)
Dedicated LBD program with clinical trials, support groups, caregiver education, and multidisciplinary care.

University of Florida — Norman Fixel Institute for Neurological Diseases

Location: Gainesville, FL · Phone: 352-294-5400
Movement disorders and cognitive neurology. LBD clinical trials. DaTscan and biomarker studies.

University of Pennsylvania — Penn Memory Center and Parkinson’s Disease and Movement Disorders Center

Location: Philadelphia, PA · Phone: 215-662-7810
Leading LBD research including alpha-synuclein biomarker studies, clinical trials, and neuropathology.

University of California San Diego — Shiley-Marcos Alzheimer’s Disease Research Center

Location: La Jolla, CA · Phone: 858-822-4800
NIH ADRC with DLB research. Clinical trials for DLB and PDD. Douglas Galasko LBD expertise.

Massachusetts General Hospital — Movement Disorders and Memory Disorders Units

Location: Boston, MA · Phone: 617-726-2000
Harvard-affiliated. LBD clinical trials. Advanced neuroimaging. Alpha-synuclein SAA research.

VA Neurodegenerative Disease Care

The VA system provides dementia and movement disorder care through its network of medical centers. For LBD-specific expertise, the VA typically partners with academic centers through community care arrangements. Veterans should ask their VA neurologist about:

Referral to an academic movement disorder or cognitive neurology center for second opinion
Community care authorization for LBD-specific specialist evaluation
Clinical trial access through VA-academic partnerships
VA PADRECC (Parkinson’s Disease Research, Education, and Clinical Centers) — 6 centers nationally with PD/LBD expertise

George E. Wahlen VA Medical Center, Salt Lake City: 801-582-1565
VA Caregiver Support Line: 1-855-260-3274
VA PADRECC locations: Philadelphia, Houston, San Francisco, Portland, Richmond, West Los Angeles

University Health Network — Toronto Western Hospital Movement Disorders Centre

Location: Toronto, ON
Phone: 416-603-5800
Programs: Leading Canadian movement disorder center. PDD and DLB evaluation. Clinical trials through the Parkinson Foundation Centre of Excellence.

McGill University — Montreal Neurological Institute

Location: Montréal, QC
Phone: 514-398-6644
Programs: Movement disorders, dementia, clinical trials. Parkinson’s and Lewy body research.

University of British Columbia — Pacific Parkinson’s Research Centre

Location: Vancouver, BC
Phone: 604-822-7764
Programs: Parkinson’s and related disorders including PDD/DLB. DaTscan, clinical trials, brain donation program.

Alzheimer Society of Canada: alzheimer.ca
Parkinson Canada: parkinson.ca
Canadian dementia helpline: 1-855-705-4636

International Centers of Excellence for LBD

Newcastle University — Campus for Ageing and Vitality, Newcastle upon Tyne, UK: Led the development of DLB diagnostic criteria (Ian McKeith). One of the world’s leading DLB research centers.
King’s College London — Institute of Psychiatry, Psychology & Neuroscience, UK: DLB clinical trials and biomarker research.
Keio University Hospital, Tokyo, Japan: DLB diagnosis and treatment including MIBG scintigraphy, which is more widely used in Japan than elsewhere.
Karolinska Institutet, Stockholm, Sweden: Alpha-synuclein biomarker development and DLB research.
University of Sydney — Brain and Mind Centre, Australia: Lewy body research and clinical trials.

Caregiver Guidance

Caring for someone with LBD is among the most demanding forms of caregiving. The combination of cognitive fluctuations, visual hallucinations, motor disability, sleep disturbances, and behavioral changes creates challenges that are different from and often more complex than Alzheimer’s disease caregiving.

Fluctuating cognition is a core feature, not a sign that you are doing something wrong. Some days the person may seem nearly normal; other days they may be confused, drowsy, or unresponsive. This unpredictability is one of the most challenging aspects for caregivers.
Use “good periods” for important activities, decisions, and communication.
During “off” periods, provide a calm, safe environment. Do not force activity or interaction.
Track patterns — some patients fluctuate at predictable times of day.
Sudden worsening may indicate infection (especially urinary tract infection), medication change, dehydration, or constipation — not necessarily disease progression.

Do not argue. The person with LBD genuinely sees what they are describing. Telling them it is not real is frustrating and ineffective.
Redirect and reassure: Calmly acknowledge their experience, then redirect attention to something else.
Assess distress level: If hallucinations are not causing fear or agitation, they may not need treatment.
Improve the environment: Good lighting (reduce shadows), remove mirrors if causing misidentification, reduce visual clutter.
Report changes: New or worsening hallucinations should be reported to the neurologist — medication adjustments may be needed.

Fall prevention: Remove rugs, install grab bars, improve lighting, consider a raised toilet seat and shower chair. Falls are the leading cause of injury in LBD.
Night safety: Pad the bed area, remove bedside tables with sharp edges, consider bed rails or a mattress on the floor for RBD.
Driving: Cognitive fluctuations and visuospatial impairment make driving dangerous. This is one of the hardest conversations but one of the most important. A formal driving evaluation may help.
Medication management: Take over medication management early. Keep a current medication list and share it at every medical visit. Carry the wallet card about antipsychotic sensitivity.
Wandering: Less common than in Alzheimer’s but can occur. Consider GPS tracking devices, door alarms, and MedicAlert + Safe Return (Alzheimer’s Association).

Caregiver burnout rates for LBD are among the highest of any dementia. Depression, anxiety, and physical health decline are common among LBD caregivers. This is not a failure — it reflects the extraordinary demands of the disease.
Accept help. You cannot do this alone. Organize a care team (family, friends, home health aides, adult day programs).
Respite care: Use respite services regularly, not just in emergencies. Contact the LBDA (1-800-539-9767) for resources.
Join a support group: LBDA offers both in-person and online support groups specifically for LBD caregivers. Connecting with others who understand the unique challenges of LBD is invaluable.
Plan ahead: Advance directives, power of attorney (financial and healthcare), long-term care planning should be done as early as possible while the person with LBD can still participate.

Key resources:

Lewy Body Dementia Association (LBDA): 1-800-539-9767 · lbda.org
Alzheimer’s Association 24/7 Helpline: 1-800-272-3900 (covers all dementias including LBD)
National Alliance for Caregiving: caregiving.org
ARCH National Respite Network: archrespite.org

Reproductive-Age Considerations & Lewy Body Dementia

Lewy body dementia predominantly affects adults over 65 and is exceptionally rare in people of reproductive age. Pregnancy concurrent with LBD is not a recognized clinical scenario. However, the following information is relevant for younger caregivers and for rare younger-onset cases.

Medication safety for pregnant caregivers

Family members or caregivers who are pregnant and who handle LBD medications should take precautions:

Rivastigmine patches (Exelon) — avoid skin contact with the patch during pregnancy; wear gloves when applying or removing. Accidental skin absorption is a theoretical risk.
Clonazepam — a known teratogen (benzodiazepine); pregnant caregivers should not handle crushed or split tablets without gloves, and should ensure safe storage.
Levodopa-carbidopa — animal data suggest potential fetal harm; pregnant caregivers handling these medications should avoid crushing tablets (dust inhalation).

Genetic counseling for family members

LBD has both sporadic and genetic forms. Family members of reproductive age who are concerned about their own risk may consider genetic counseling, particularly if there is a strong family history of LBD or Parkinson disease. Relevant genes include GBA (glucocerebrosidase) and SNCA (alpha-synuclein). Genetic counseling through the University of Utah Department of Neurology or Huntsman Cancer Institute is available; ask your neurologist for a referral.

Note: If you or a family member of reproductive age is experiencing cognitive or movement symptoms at a young age, discuss genetic testing with a neurologist. Early-onset LBD is extremely rare but warrants specialist evaluation.

Glossary

Alpha-synuclein: A protein that misfolds and accumulates in Lewy bodies, the pathological hallmark of LBD and Parkinson’s disease.
Autonomic dysfunction: Failure of the autonomic nervous system, causing problems with blood pressure, digestion, bladder control, and temperature regulation.
Bradykinesia: Slowness of movement, a cardinal feature of parkinsonism.
Capgras syndrome: A delusion that a family member or caregiver has been replaced by an identical impostor. Common in LBD.
Cholinesterase inhibitor: A class of drugs (rivastigmine, donepezil, galantamine) that increase acetylcholine levels in the brain. First-line treatment for LBD cognitive symptoms.
Cognitive fluctuations: Spontaneous, unpredictable variations in attention and alertness, often occurring over hours or days. A core feature of DLB.
DaTscan: A nuclear medicine imaging test that measures dopamine transporter levels. Reduced uptake supports a diagnosis of DLB or Parkinson’s disease.
DLB: Dementia with Lewy bodies. The form of LBD where cognitive symptoms appear before or within one year of motor symptoms.
Dopamine: A brain chemical important for movement, motivation, and reward. Depleted in Parkinson’s disease and LBD.
GBA: Glucocerebrosidase gene. Variants in GBA increase risk for Parkinson’s disease and LBD.
Lewy bodies: Abnormal clumps of alpha-synuclein protein found inside neurons in the brains of people with LBD and Parkinson’s disease.
MIBG scintigraphy: A nuclear medicine test that measures sympathetic nerve function in the heart. Reduced uptake supports a Lewy body diagnosis.
Neuroleptic sensitivity: An exaggerated and potentially life-threatening adverse reaction to antipsychotic medications, characteristic of LBD.
Orthostatic hypotension: A drop in blood pressure upon standing, causing dizziness and risk of falls. Common in LBD.
Parkinsonism: Motor symptoms resembling Parkinson’s disease: bradykinesia, rigidity, tremor, and postural instability.
PDD: Parkinson’s disease dementia. Dementia developing in a person with established Parkinson’s disease (motor symptoms preceding cognitive symptoms by at least one year).
Pimavanserin (Nuplazid): A selective serotonin inverse agonist approved for Parkinson’s disease psychosis. Does not block dopamine. The safest antipsychotic option for LBD.
RBD (REM sleep behavior disorder): A sleep disorder where the normal paralysis during REM sleep is absent, causing people to physically act out vivid dreams.
Rivastigmine (Exelon): A cholinesterase inhibitor with the strongest evidence for cognitive and behavioral symptoms in LBD. Available as a patch or capsule.
SAA (seed amplification assay): A laboratory test that detects misfolded alpha-synuclein in cerebrospinal fluid with high accuracy for diagnosing synucleinopathies.
Synucleinopathy: A group of diseases characterized by abnormal alpha-synuclein accumulation, including Parkinson’s disease, DLB, PDD, and multiple system atrophy.
Visuospatial dysfunction: Difficulty perceiving spatial relationships, judging distances, navigating, or recognizing objects. Prominent early in DLB.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians and researchers treating and studying Lewy body dementia across multiple countries. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
Lewy Body Dementia Association (LBDA) (lbda.org) — Patient education, caregiver support, research updates (1-800-539-9767)
National Institute on Aging (NIA) (nia.nih.gov) — Comprehensive LBD information
Alzheimer’s Association (alz.org) — LBD information and 24/7 helpline (1-800-272-3900)
Lewy Body Society (UK) (lewybody.org) — UK patient and carer resources
Michael J. Fox Foundation (michaeljfox.org) — Parkinson’s and related disorders research

Key Guideline and Trial References

Fourth Consensus DLB Criteria: McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.
NICE NG97: Dementia — assessment, management and support for people living with dementia and their carers. National Institute for Health and Care Excellence.
MDS PDD Criteria: Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders. 2007;22(12):1689–1707.
PASADENA: Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med. 2022;387(5):421–432. (NCT03100149)
SPARK (cinpanemab): Lang AE, Siderowf AD, Macklin EA, et al. Trial of cinpanemab in early Parkinson’s disease. N Engl J Med. 2022;387(5):408–420. (NCT03318523)
HARMONY (pimavanserin): Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med. 2021;385(4):309–319. (NCT03325556)
Rivastigmine in PDD: Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–2518.
Alpha-synuclein SAA: Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–417.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

Key Search Terms for ClinicalTrials.gov and PubMed

“dementia with Lewy bodies rivastigmine”
“Lewy body dementia donepezil”
“pimavanserin dementia-related psychosis HARMONY”
“REM sleep behavior disorder melatonin clonazepam”
“Parkinson disease dementia rivastigmine”
“DaTscan DLB Alzheimer differentiation”

“prasinezumab alpha-synuclein PASADENA PADOVA”
“alpha-synuclein seed amplification assay CSF”
“GLP-1 agonist neuroprotection Parkinson”
“venglustat GBA Parkinson Lewy body”
“neflamapimod DLB AscenD-LB RewinD-LB”

A practical test for any online claim: If a website is making a claim about LBD treatment that does not appear anywhere in PubMed, the LBDA website, or established guidelines (McKeith 2017, NICE NG97), that should be a significant warning sign.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose or treat anyone. It does not know your specific symptoms, biomarker results, medication history, or personal preferences. Only your medical team can build an actual plan.
LBD research is evolving. New diagnostic tools, trial results, and treatment approaches emerge regularly. Every time-sensitive fact should be re-verified with your team and primary sources.
Drug availability varies by country. This guide discusses medications available in multiple countries but focuses on the United States. Access differs in Europe, Asia, Canada, and other regions.
Individual experiences vary enormously. Some people with LBD live well for many years; others decline more rapidly. Prognostic estimates describe populations, not individuals.
Care is not equal everywhere. This guide describes best practices at well-resourced academic centers. Referral to a movement disorder or cognitive neurology specialist is often the single highest-value step a patient can take.

A final word. Lewy body dementia is a challenging diagnosis. The combination of cognitive, motor, psychiatric, and sleep symptoms can feel overwhelming. But accurate diagnosis, specialist care, appropriate medications (and avoidance of dangerous ones), and strong caregiver support can meaningfully improve quality of life. You are not alone. The Lewy Body Dementia Association (1-800-539-9767) and the Alzheimer’s Association (1-800-272-3900) are available to help. Use them.